Symptomatic Aortic Stenosis
23
3
6
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
4.3%
1 terminated out of 23 trials
92.3%
+5.8% vs benchmark
13%
3 trials in Phase 3/4
50%
6 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (23)
DurAVR™ THV EU-EFS
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
Optimize PRO Study
China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population
Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System
Structured Shared Decision Making for Patients Undergoing SAVR or TAVR
DurAVR™ THV System: First-In-Human Study
China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population
Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation
Image Fusion and Calcification Raising in Trans Aortic Valve Implantation
Transcatheter Aortic Valve Replacement Single Center Registry in Chinese Population
Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
Geriatric Evaluation to Predict Mortality and Functional Recovery After Trans Aortic Valve Implantation
Portico TAVI Implant With Transfemoral Delivery System
Assessment of the St. Jude Medical PorticoTM Re-sheathable Aortic Valve System - Alternative Access
First in Human Experience of the St. Jude Medical TAVI Valve and Delivery System
ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis:CE-approval Cohort
Women's INternational Transcatheter Aortic Valve Implantation Registry